Moreover, targeting Akt anti-cancer therapy should be considered not only for patients harboring related mutations such as PTEN loss, but also in patients without obvious Akt pathway hyperactivations, because this is part of the survival mechanism for this disease. This evidence concerns the gene AKT1 and cancer.